Research Article
Multiple Myeloma Patients at Various Cytogenetic Risks Benefit Differently from Autologous Stem Cell Transplantation as a Consolidation Therapy
Figure 6
Comparison of OS in the patients of ASCT group and non-ASCT group in the intermediate-risk subgroup. The median OS was 54 versus 42.1 months with no significant difference ().